Moderna Seeks Expedited FDA Approval for Personalized mRNA Melanoma Therapy Intismeran

Moderna CEO Stéphane Bancel announced the company's intention to secure U.S. Food and Drug Administration (FDA) approval for its personalized mRNA therapy, intismeran, as soon as possible. This follows positive Phase III trial results demonstrating improved treatment outcomes for patients with melanoma. The announcement was made during the annual meeting of the European Society for Medical Oncology in Madrid, Spain.